Search Results

There are 3994 results for: content related to: Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

  1. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Reena Khanna, Jan C Preiss, John K MacDonald and Antje Timmer

    Published Online : 5 MAY 2015, DOI: 10.1002/14651858.CD007572.pub2

  2. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 6, June 2014, Pages: 790–798, K.A. Papp, M. Sundaram, Y. Bao, D.A. Williams, Y. Gu, J.E. Signorovitch, Y. Wang, J.M. Valdes and P.M. Mulani

    Article first published online : 17 MAY 2013, DOI: 10.1111/jdv.12177

  3. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 10, October 2013, Pages: 1252–1261, R.G. Langley, K. Papp, A.B. Gottlieb, G.G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze and B. Strober

    Article first published online : 16 NOV 2012, DOI: 10.1111/j.1468-3083.2012.04705.x

  4. You have free access to this content
    Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

    British Journal of Pharmacology

    Volume 160, Issue 4, June 2010, Pages: 810–820, Wolfgang Weger

    Article first published online : 1 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00702.x

  5. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

    British Journal of Dermatology

    Volume 165, Issue 3, September 2011, Pages: 661–668, B.E. Strober, J.J. Crowley, P.S. Yamauchi, M. Olds and D.A. Williams

    Article first published online : 28 JUL 2011, DOI: 10.1111/j.1365-2133.2011.10419.x

  6. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

    British Journal of Dermatology

    Volume 165, Issue 3, September 2011, Pages: 652–660, A.B. Gottlieb, C. Leonardi, F. Kerdel, S. Mehlis, M. Olds and D.A. Williams

    Article first published online : 4 AUG 2011, DOI: 10.1111/j.1365-2133.2011.10418.x

  7. You have free access to this content
    Interleukin-23: as a drug target for autoimmune inflammatory diseases

    Immunology

    Volume 135, Issue 2, February 2012, Pages: 112–124, Chunlei Tang, Shu Chen, Hai Qian and Wenlong Huang

    Article first published online : 11 JAN 2012, DOI: 10.1111/j.1365-2567.2011.03522.x

  8. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue s5, August 2012, Pages: 2–8, Christopher E.M. Griffiths and Giampiero Girolomoni

    Article first published online : 3 JUL 2012, DOI: 10.1111/j.1468-3083.2012.04604.x

  9. Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 3, September 2012, Pages: 306–320, D A Katzka, E V Loftus Jr and M Camilleri

    Article first published online : 25 JUL 2012, DOI: 10.1038/clpt.2012.77

  10. Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1586–1587, T. Tzellos, A. Kyrgidis, A. Trigoni and C.C. Zouboulis

    Article first published online : 6 MAR 2013, DOI: 10.1111/jdv.12126

  11. You have free access to this content
    Preclinical development of AMG 139, a human antibody specifically targeting IL-23

    British Journal of Pharmacology

    Volume 172, Issue 1, January 2015, Pages: 159–172, K Köck, W J Pan, J M Gow, M J Horner, J P Gibbs, A Colbert, T J Goletz, K J Newhall, W A Rees, Y Sun, Y Zhang, J C O'Neill, A N Umble-Romero, S P Prokop, C D Krill, L Som, S A Buntich, M W Trimble, W H Tsuji and J E Towne

    Article first published online : 15 DEC 2014, DOI: 10.1111/bph.12904

  12. You have free access to this content
    A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis

    Experimental Dermatology

    Volume 20, Issue 7, July 2011, Pages: 544–549, April W. Armstrong, Stephanie V. Voyles, Ehrin J. Armstrong, Erin N. Fuller and John C. Rutledge

    Article first published online : 22 JUN 2011, DOI: 10.1111/j.1600-0625.2011.01308.x

  13. Is ‘class effect’ relevant when assessing the benefit/risk profile of a biologic agent?

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue s5, August 2012, Pages: 9–16, W. Sterry and P. van de Kerkhof

    Article first published online : 3 JUL 2012, DOI: 10.1111/j.1468-3083.2012.04605.x

  14. An updated survey for the 2007–2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship

    Journal of the European Academy of Dermatology and Venereology

    I.F. Manalo, K.E. Gilbert and J.J. Wu

    Article first published online : 12 MAR 2015, DOI: 10.1111/jdv.13089

  15. You have free access to this content
    On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 2, April 2015, Pages: 131–134, L. Puig

    Article first published online : 27 JAN 2015, DOI: 10.1111/jcpt.12243

  16. You have free access to this content
    The impact of biological interventions for ulcerative colitis on health-related quality of life

    Intervention Protocol

    The Cochrane Library

    Katie LeBlanc, Mahmoud Mosli, Kenneth A Baker and John K MacDonald

    Published Online : 6 JUN 2013, DOI: 10.1002/14651858.CD008655.pub2

  17. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association

    Dermatologic Therapy

    Volume 23, Issue 2, March/April 2010, Pages: 101–113, Kristina Callis Duffin, Jamie Woodcock and Gerald G. Krueger

    Article first published online : 25 MAR 2010, DOI: 10.1111/j.1529-8019.2010.01303.x

  18. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 7, July 2013, Pages: 861–866, M. Inzinger, W. Weger, B. Heschl, W. Salmhofer, F. Quehenberger and P. Wolf

    Article first published online : 2 JUN 2012, DOI: 10.1111/j.1468-3083.2012.04596.x

  19. You have free access to this content
    Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets

    British Journal of Pharmacology

    Volume 166, Issue 3, June 2012, Pages: 806–822, Pauline L Martin and Peter J Bugelski

    Article first published online : 8 MAY 2012, DOI: 10.1111/j.1476-5381.2011.01812.x

  20. You have free access to this content
    Can treatment of the skin rescue the heart?

    Journal of Internal Medicine

    Volume 273, Issue 2, February 2013, Pages: 186–188, M. Ståhle

    Article first published online : 12 NOV 2012, DOI: 10.1111/joim.12008